Ann M. Arvin

Publications

• Anti-Glycoprotein H Antibody Impairs the Pathogenicity of Varicella-Zoster Virus in Skin Xenografts in the SCID Mouse Model. Vleck SE, Oliver SL, Reichelt M, Rajamani J, Zerboni L, Jones C, Zehnder J, Grose C, Arvin AM. J Virol. 2009
• Mutagenesis of varicella-zoster virus glycoprotein B: putative fusion loop residues are essential for viral replication, and the furin cleavage motif contributes to pathogenesis in skin tissue in vivo. Oliver SL, Sommer M, Zerboni L, Rajamani J, Grose C, Arvin AM. J Virol. 2009; 83 (15): 7495-506
• Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis. Wang L, Sommer M, Rajamani J, Arvin AM. J Virol. 2009; 83 (15): 7560-72
• The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. Reichelt M, Brady J, Arvin AM. J Virol. 2009; 83 (8): 3904-18
• Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry. Berarducci B, Rajamani J, Reichelt M, Sommer M, Zerboni L, Arvin AM. J Virol. 2009; 83 (1): 228-40
• Functions of the ORF9-to-ORF12 gene cluster in varicella-zoster virus replication and in the pathogenesis of skin infection. Che X, Reichelt M, Sommer MH, Rajamani J, Zerboni L, Arvin AM. J Virol. 2008; 82 (12): 5825-34
• Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. Reichelt M, Zerboni L, Arvin AM. J Virol. 2008; 82 (8): 3971-83
• The ubiquitous cellular transcriptional factor USF targets the varicella-zoster virus open reading frame 10 promoter and determines virulence in human skin xenografts in SCIDhu mice in vivo. Che X, Berarducci B, Sommer M, Ruyechan WT, Arvin AM. J Virol. 2007; 81 (7): 3229-39
• Cellular and viral factors regulate the varicella-zoster virus gE promoter during viral replication. Berarducci B, Sommer M, Zerboni L, Rajamani J, Arvin AM. J Virol. 2007; 81 (19): 10258-67
• Aberrant infection and persistence of varicella-zoster virus in human dorsal root ganglia in vivo in the absence of glycoprotein I. Zerboni L, Reichelt M, Jones CD, Zehnder JL, Ito H, Arvin AM. Proc Natl Acad Sci U S A. 2007; 104 (35): 14086-91
• Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo. Jones JO, Arvin AM. J Virol. 2006; 80 (11): 5113-24
• Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection. Berarducci B, Ikoma M, Stamatis S, Sommer M, Grose C, Arvin AM. J Virol. 2006; 80 (19): 9481-96
• Varicella-zoster virus infection of human dorsal root ganglia in vivo. Zerboni L, Ku CC, Jones CD, Zehnder JL, Arvin AM. Proc Natl Acad Sci U S A. 2005; 102 (18): 6490-5
• Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. Ku CC, Besser J, Abendroth A, Grose C, Arvin AM. J Virol. 2005; 79 (5): 2651-8
• Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. Ku CC, Zerboni L, Ito H, Graham BS, Wallace M, Arvin AM. J Exp Med. 2004; 200 (7): 917-25
• Varicella in the fetus and newborn. Smith CK, Arvin AM. Semin Fetal Neonatal Med. 2009; 14 (4): 209-17
• One step closer to a CMV vaccine. Dekker CL, Arvin AM. N Engl J Med. 2009; 360 (12): 1250-2
• Age-Related Increase in the Frequency of CD4(+) T Cells That Produce Interferon-gamma in Response to Staphylococcal Enterotoxin B during Childhood. Hanna-Wakim R, Yasukawa LL, Sung P, Fang M, Sullivan B, Rinki M, Dehovitz R, Arvin AM, Gans HA. J Infect Dis. 2009; 200 (12): 1921-1927
• Influence of prior influenza vaccination on antibody and B-cell responses. Sasaki S, He XS, Holmes TH, Dekker CL, Kemble GW, Arvin AM, Greenberg HB. PLoS One. 2008; 3 (8): e2975
• Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts. Oliver SL, Zerboni L, Sommer M, Rajamani J, Arvin AM. J Virol Methods. 2008; 154 (1-2): 182-93
• Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. He XS, Holmes TH, Sasaki S, Jaimes MC, Kemble GW, Dekker CL, Arvin AM, Greenberg HB. PLoS One. 2008; 3 (7): e2574
• Functions of Varicella-zoster virus ORF23 capsid protein in viral replication and the pathogenesis of skin infection. Chaudhuri V, Sommer M, Rajamani J, Zerboni L, Arvin AM. J Virol. 2008; 82 (20): 10231-46
• Humoral and cellular immunity to varicella-zoster virus: an overview. Arvin AM, J Infect Dis. 2008: 197 Suppl 2 S58-60
• Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants. Gans HA, Yasukawa LL, Zhang CZ, Wakim RH, Rinki M, Dehovitz R, Arvin AM. Viral Immunol. 2008; 21 (2): 163-72
• Immune responses to mumps vaccine in adults who were vaccinated in childhood. Hanna-Wakim R, Yasukawa LL, Sung P, Arvin AM, Gans HA. J Infect Dis. 2008; 197 (12): 1669-75
• Primary vaccine failure after 1 dose of varicella vaccine in healthy children. Michalik DE, Steinberg SP, Larussa PS, Edwards KM, Wright PF, Arvin AM, Gans HA, Gershon AA. J Infect Dis. 2008; 197 (7): 944-9
• Varicella vaccine in the United States: a decade of prevention and the way forward. Gershon AA, Arvin AM, Levin MJ, Seward JF, Schmid DS. J Infect Dis. 2008: 197 Suppl 2 S39-40
• Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. He XS, Holmes TH, Mahmood K, Kemble GW, Dekker CL, Arvin AM, Greenberg HB. J Infect Dis. 2008; 197 (6): 803-11
• Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. Sasaki S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW, Arvin AM, Greenberg HB. J Virol. 2007; 81 (1): 215-28
• A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. Tischer BK, Kaufer BB, Sommer M, Wussow F, Arvin AM, Osterrieder N. J Virol. 2007; 81 (23): 13200-8
• Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. Nair N, Gans H, Lew-Yasukawa L, Long-Wagar AC, Arvin A, Griffin DE. J Infect Dis. 2007; 196 (9): 1339-45
• Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Zeman AM, Holmes TH, Stamatis S, Tu W, He XS, Bouvier N, Kemble G, Greenberg HB, Lewis DB, Arvin AM, Dekker CL. Pediatr Infect Dis J. 2007; 26 (2): 107-15
• Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes. Brown EL, Gardella C, Malm G, Prober CG, Forsgren M, Krantz EM, Arvin AM, Yasukawa LL, Mohan K, Brown Z, Corey L, Wald A. Acta Obstet Gynecol Scand. 2007; 86 (5): 523-9
• Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system. Zhang Z, Rowe J, Wang W, Sommer M, Arvin A, Moffat J, Zhu H. J Virol. 2007; 81 (17): 9024-33
• ORF66 protein kinase function is required for T-cell tropism of varicella-zoster virus in vivo. Schaap-Nutt A, Sommer M, Che X, Zerboni L, Arvin AM. J Virol. 2006; 80 (23): 11806-16
• Investigations of the pathogenesis of Varicella zoster virus infection in the SCIDhu mouse model. Arvin AM, Herpes. 2006; 13 (3): 75-80
• Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, Dekker CL, Greenberg HB, Arvin AM. J Virol. 2006; 80 (23): 11756-66
• Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. Klein NP, Holmes TH, Sharp MA, Heineman TC, Schleiss MR, Bernstein DI, Kemble G, Arvin AM, Dekker CL. Vaccine. 2006; 24 (33-34): 5913-8
• Control of varicella: why is a two-dose schedule necessary? Arvin A, Gershon A. Pediatr Infect Dis J. 2006; 25 (6): 475-6
• Varicella-zoster virus open reading frame 10 is a virulence determinant in skin cells but not in T cells in vivo. Che X, Zerboni L, Sommer MH, Arvin AM. J Virol. 2006; 80 (7): 3238-48
• Mutational analysis of the varicella-zoster virus ORF62/63 intergenic region. Jones JO, Sommer M, Stamatis S, Arvin AM. J Virol. 2006; 80 (6): 3116-21
• New viral vaccines. Arvin AM, Greenberg HB. Virology. 2006; 344 (1): 240-9
• Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Wong-Chew RM, Islas-Romero R, García-García Mde L, Beeler JA, Audet S, Santos-Preciado JI, Gans H, Lew-Yasukawa L, Maldonado YA, Arvin AM, Valdespino-Gómez JL. Vaccine. 2006; 24 (5): 683-90
• Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons. Hood C, Cunningham AL, Slobedman B, Arvin AM, Sommer MH, Kinchington PR, Abendroth A. J Virol. 2006; 80 (2): 1025-31
• A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. Heineman TC, Schleiss M, Bernstein DI, Spaete RR, Yan L, Duke G, Prichard M, Wang Z, Yan Q, Sharp MA, Klein N, Arvin AM, Kemble G. J Infect Dis. 2006; 193 (10): 1350-60
• Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. Brown EL, Morrow R, Krantz EM, Arvin AM, Prober CG, Yasukawa LL, Corey L, Wald A. Am J Obstet Gynecol. 2006; 195 (1): 115-20
• Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Zerboni L, Hinchliffe S, Sommer MH, Ito H, Besser J, Stamatis S, Cheng J, Distefano D, Kraiouchkine N, Shaw A, Arvin AM. Virology. 2005; 332 (1): 337-46
• Aging, immunity, and the varicella-zoster virus. Arvin A, N Engl J Med. 2005; 352 (22): 2266-7
• T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection. Schaap A, Fortin JF, Sommer M, Zerboni L, Stamatis S, Ku CC, Nolan GP, Arvin AM. J Virol. 2005; 79 (20): 12921-33
• Reducing the global burden of congenital rubella syndrome: report of the World Health Organization Steering Committee On Research Related To Measles and Rubella Vaccines and Vaccination, June 2004. Best JM, Castillo-Solorzano C, Spika JS, Icenogle J, Glasser JW, Gay NJ, Andrus J, Arvin AM. J Infect Dis. 2005; 192 (11): 1890-7
• Role of the varicella-zoster virus gene product encoded by open reading frame 35 in viral replication in vitro and in differentiated human skin and T cells in vivo. Ito H, Sommer MH, Zerboni L, Baiker A, Sato B, Liang R, Hay J, Ruyechan W, Arvin AM. J Virol. 2005; 79 (8): 4819-27
• Cell-type-dependent activation of the cellular EF-1alpha promoter by the varicella-zoster virus IE63 protein. Zuranski T, Nawar H, Czechowski D, Lynch JM, Arvin A, Hay J, Ruyechan WT. Virology. 2005; 338 (1): 35-42
• Chickenpox party or varicella vaccine? Hambleton S, Arvin AM. Adv Exp Med Biol. 2005: 568 11-24
• Strengthening the nation's influenza vaccination system: a National Vaccine Advisory Committee assessment. Helms CM, Guerra FA, Klein JO, Schaffner W, Arvin AM, Peter G. Am J Prev Med. 2005; 29 (3): 221-6
• Viral and cellular gene transcription in fibroblasts infected with small plaque mutants of varicella-zoster virus. Jones JO, Arvin AM. Antiviral Res. 2005; 68 (2): 56-65
• Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. Clin Infect Dis. 2004; 39 (2): 233-9
• T cell immunity to measles viral proteins in infants and adults after measles immunization. Gans HA, Yasukawa LL, Alderson A, Rinki M, Dehovitz R, Maldonado Y, Arvin AM. Viral Immunol. 2004; 17 (2): 298-307
• Varicella-zoster virus infection of human neural cells in vivo. Baiker A, Fabel K, Cozzio A, Zerboni L, Fabel K, Sommer M, Uchida N, He D, Weissman I, Arvin AM. Proc Natl Acad Sci U S A. 2004; 101 (29): 10792-7
• Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, Audet S, Maldonado Y, Arvin AM. J Infect Dis. 2004; 190 (1): 83-90
• Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood. Chen SF, Tu WW, Sharp MA, Tongson EC, He XS, Greenberg HB, Holmes TH, Wang Z, Kemble G, Manganello AM, Adler SP, Dekker CL, Lewis DB, Arvin AM. J Infect Dis. 2004; 189 (9): 1619-27
• Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. Tu W, Chen S, Sharp M, Dekker C, Manganello AM, Tongson EC, Maecker HT, Holmes TH, Wang Z, Kemble G, Adler S, Arvin A, Lewis DB. J Immunol. 2004; 172 (5): 3260-7
• The immediate-early 63 protein of Varicella-Zoster virus: analysis of functional domains required for replication in vitro and for T-cell and skin tropism in the SCIDhu model in vivo. Baiker A, Bagowski C, Ito H, Sommer M, Zerboni L, Fabel K, Hay J, Ruyechan W, Arvin AM. J Virol. 2004; 78 (3): 1181-94
• T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. He XS, Draghi M, Mahmood K, Holmes TH, Kemble GW, Dekker CL, Arvin AM, Parham P, Greenberg HB. J Clin Invest. 2004; 114 (12): 1812-9
• Differential requirement for cell fusion and virion formation in the pathogenesis of varicella-zoster virus infection in skin and T cells. Besser J, Ikoma M, Fabel K, Sommer MH, Zerboni L, Grose C, Arvin AM. J Virol. 2004; 78 (23): 13293-305
• Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo. Moffat J, Mo C, Cheng JJ, Sommer M, Zerboni L, Stamatis S, Arvin AM. J Virol. 2004; 78 (22): 12406-15
• Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. Wong-Chew RM, Islas-Romero R, García-García Mde L, Beeler JA, Audet S, Santos-Preciado JI, Gans H, Lew-Yasukawa L, Maldonado YA, Arvin AM, Valdespino-Gómez JL. J Infect Dis. 2004; 189 (2): 254-7
• Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee. Santoli JM, Peter G, Arvin AM, Davis JP, Decker MD, Fast P, Guerra FA, Helms CM, Hinman AR, Katz R, Klein JO, Koslap-Petraco MB, Paradiso PR, Schaffner W, Whitley-Williams PN, Williamson DE, Gellin B. JAMA. 2003; 290 (23): 3122-8
• Microarray analysis of host cell gene transcription in response to varicella-zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo. Jones JO, Arvin AM. J Virol. 2003; 77 (2): 1268-80
• Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. Frey CR, Sharp MA, Min AS, Schmid DS, Loparev V, Arvin AM. J Infect Dis. 2003; 188 (1): 40-52
• Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Gans H, DeHovitz R, Forghani B, Beeler J, Maldonado Y, Arvin AM. Vaccine. 2003; 21 (24): 3398-405
• Requirement of varicella-zoster virus immediate-early 4 protein for viral replication. Sato B, Sommer M, Ito H, Arvin AM. J Virol. 2003; 77 (22): 12369-72
• Promoter sequences of varicella-zoster virus glycoprotein I targeted by cellular transactivating factors Sp1 and USF determine virulence in skin and T cells in SCIDhu mice in vivo. Ito H, Sommer MH, Zerboni L, He H, Boucaud D, Hay J, Ruyechan W, Arvin AM. J Virol. 2003; 77 (1): 489-98
• Varicella-zoster virus infection facilitates VZV glycoprotein E trafficking to the membrane surface of melanoma cells. Mo C, Lee J, Sommer MH, Arvin AM. J Med Virol. 2003: 70 Suppl 1 S56-8
• Analysis of the frequencies and of the memory T cell phenotypes of human CD8+ T cells specific for influenza A viruses. He XS, Mahmood K, Maecker HT, Holmes TH, Kemble GW, Arvin AM, Greenberg HB. J Infect Dis. 2003; 187 (7): 1075-84
• Long term antiviral suppression after treatment for neonatal herpes infection. Gutierrez K, Arvin AM. Pediatr Infect Dis J. 2003; 22 (4): 371-2
• Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo. Sato B, Ito H, Hinchliffe S, Sommer MH, Zerboni L, Arvin AM. J Virol. 2003; 77 (10): 5607-20
• Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model. Niizuma T, Zerboni L, Sommer MH, Ito H, Hinchliffe S, Arvin AM. J Virol. 2003; 77 (10): 6062-5
• Differentiation of varicella-zoster virus ORF47 protein kinase and IE62 protein binding domains and their contributions to replication in human skin xenografts in the SCID-hu mouse. Besser J, Sommer MH, Zerboni L, Bagowski CP, Ito H, Moffat J, Ku CC, Arvin AM. J Virol. 2003; 77 (10): 5964-74
• Glycoprotein I of varicella-zoster virus is required for viral replication in skin and T cells. Moffat J, Ito H, Sommer M, Taylor S, Arvin AM. J Virol. 2002; 76 (16): 8468-71
• The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Mo C, Lee J, Sommer M, Grose C, Arvin AM. Virology. 2002; 304 (2): 176-86
• Debate: the argument against. Should all pregnant women be offered type-specific serological screening for HSV infection? Arvin AM, Herpes. 2002; 9 (2): 48-50
• Antiviral therapy for varicella and herpes zoster. Arvin AM, Semin Pediatr Infect Dis. 2002; 13 (1): 12-21
• Latent cytomegalovirus down-regulates major histocompatibility complex class II expression on myeloid progenitors. Slobedman B, Mocarski ES, Arvin AM, Mellins ED, Abendroth A. Blood. 2002; 100 (8): 2867-73
• Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. Ku CC, Padilla JA, Grose C, Butcher EC, Arvin AM. J Virol. 2002; 76 (22): 11425-33
• Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, Arvin AM. N Engl J Med. 2002; 347 (1): 26-34
• Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster virus. Arvin AM, Sharp M, Moir M, Kinchington PR, Sadeghi-Zadeh M, Ruyechan WT, Hay J. Viral Immunol. 2002; 15 (3): 507-16
• The molecular epidemiology of varicella-zoster virus: evidence for geographic segregation. Quinlivan M, Hawrami K, Barrett-Muir W, Aaby P, Arvin A, Chow VT, John TJ, Matondo P, Peiris M, Poulsen A, Siqueira M, Takahashi M, Talukder Y, Yamanishi K, Leedham-Green M, Scott FT, Thomas SL, Breuer J. J Infect Dis. 2002; 186 (7): 888-94
• Varlirix (GlaxoSmithKline). Arvin AM, Curr Opin Investig Drugs. 2002; 3 (7): 996-9
• Immune evasion mechanisms of varicella-zoster virus. Abendroth A, Arvin A. Arch Virol Suppl. 2001; (17): 99-107
• Varicella vaccine: genesis, efficacy, and attenuation. Arvin AM, Virology. 2001; 284 (2): 153-8
• Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. Sommer MH, Zagha E, Serrano OK, Ku CC, Zerboni L, Baiker A, Santos R, Spengler M, Lynch J, Grose C, Ruyechan W, Hay J, Arvin AM. J Virol. 2001; 75 (17): 8224-39
• Varicella-zoster virus: molecular virology and virus-host interactions. Arvin AM, Curr Opin Microbiol. 2001; 4 (4): 442-9
• Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, Audet S, Maldonado Y, Arvin AM. J Infect Dis. 2001; 184 (7): 817-26
• Granulysin blocks replication of varicella-zoster virus and triggers apoptosis of infected cells. Hata A, Zerboni L, Sommer M, Kaspar AA, Clayberger C, Krensky AM, Arvin AM. Viral Immunol. 2001; 14 (2): 125-33
• Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument. Wang ZH, Gershon MD, Lungu O, Zhu Z, Mallory S, Arvin AM, Gershon AA. J Virol. 2001; 75 (1): 323-40
• Varicella vaccine--the first six years. Arvin AM, N Engl J Med. 2001; 344 (13): 1007-9
• Immune evasion as a pathogenic mechanism of varicella zoster virus. Abendroth A, Arvin AM. Semin Immunol. 2001; 13 (1): 27-39
• Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin AM. J Virol. 2001; 75 (10): 4878-88
• Natural history of neonatal herpes simplex virus infections in the acyclovir era. Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Frenkel LM, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, de Sierra TM, Soong SJ, Kiell J, Lakeman FD, Whitley RJ. Pediatrics. 2001; 108 (2): 223-9
• Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Corey L, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, de Sierra TM, Weller S, Soong SJ, Kiell J, Lakeman FD, Whitley RJ. Pediatrics. 2001; 108 (2): 230-8
• Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Santos RA, Hatfield CC, Cole NL, Padilla JA, Moffat JF, Arvin AM, Ruyechan WT, Hay J, Grose C. Virology. 2000; 275 (2): 306-17
• Measles vaccines--a positive step toward eradicating a negative strand. Arvin AM, Nat Med. 2000; 6 (7): 744-5
• Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. Cha TA, Kao K, Zhao J, Fast PE, Mendelman PM, Arvin A. J Clin Microbiol. 2000; 38 (2): 839-45
• Glycoprotein E of varicella-zoster virus enhances cell-cell contact in polarized epithelial cells. Mo C, Schneeberger EE, Arvin AM. J Virol. 2000; 74 (23): 11377-87
• Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM. J Infect Dis. 2000; 181 (3): 859-66
• Varicella-zoster virus infection of a human CD4-positive T-cell line. Zerboni L, Sommer M, Ware CF, Arvin AM. Virology. 2000; 270 (2): 278-85
• Intravenous ribavirin therapy for adenovirus pneumonia. Shetty AK, Gans HA, So S, Millan MT, Arvin AM, Gutierrez KM. Pediatr Pulmonol. 2000; 29 (1): 69-73
• Modulation of major histocompatibility class II protein expression by varicella-zoster virus. Abendroth A, Slobedman B, Lee E, Mellins E, Wallace M, Arvin AM. J Virol. 2000; 74 (4): 1900-7
• Varicella-Zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Arvin AM, Biol Blood Marrow Transplant. 2000; 6 (3): 219-30
• Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. Jenkins DE, Yasukawa LL, Bergen R, Benike C, Engleman EG, Arvin AM. J Immunol. 1999; 162 (1): 560-7
• Characterization of Varicella-Zoster virus glycoprotein K (open reading frame 5) and its role in virus growth. Mo C, Suen J, Sommer M, Arvin A. J Virol. 1999; 73 (5): 4197-207
• IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. Gans HA, Maldonado Y, Yasukawa LL, Beeler J, Audet S, Rinki MM, DeHovitz R, Arvin AM. J Immunol. 1999; 162 (9): 5569-75
• The epidemiology of neonatal herpes simplex virus infections in California from 1985 to 1995. Gutierrez KM, Falkovitz Halpern MS, Maldonado Y, Arvin AM. J Infect Dis. 1999; 180 (1): 199-202
• Analysis of immune responses to varicella zoster viral proteins induced by DNA vaccination. Abendroth A, Slobedman B, Springer ML, Blau HM, Arvin AM. Antiviral Res. 1999; 44 (3): 179-92
• Nocardia farcinica pneumonia in chronic granulomatous disease. Shetty AK, Arvin AM, Gutierrez KM. Pediatrics. 1999; 104 (4 Pt 1): 961-4
• Management of varicella-zoster virus infections in children. Arvin AM, Adv Exp Med Biol. 1999: 458 167-74
• Chickenpox (varicella). Arvin AM, Contrib Microbiol. 1999: 3 96-110
• Development of recombinant varicella-zoster virus vaccines. Arvin AM, Mallory S, Moffat JF. Contrib Microbiol. 1999: 3 193-200
• Varicella-zoster virus immune evasion. Abendroth A, Arvin A. Immunol Rev. 1999: 168 143-56
• Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world. LaRussa P, Steinberg S, Arvin A, Dwyer D, Burgess M, Menegus M, Rekrut K, Yamanishi K, Gershon A. J Infect Dis. 1998: 178 Suppl 1 S64-6
• Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. Moffat JF, Zerboni L, Kinchington PR, Grose C, Kaneshima H, Arvin AM. J Virol. 1998; 72 (2): 965-74
• Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. Zerboni L, Nader S, Aoki K, Arvin AM. J Infect Dis. 1998; 177 (6): 1701-4
• Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. JAMA. 1998; 280 (6): 527-32
• The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Moffat JF, Zerboni L, Sommer MH, Heineman TC, Cohen JI, Kaneshima H, Arvin AM. Proc Natl Acad Sci U S A. 1998; 95 (20): 11969-74
• Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus. Jenkins DE, Redman RL, Lam EM, Liu C, Lin I, Arvin AM. J Infect Dis. 1998; 178 (4): 940-8
• Analysis of the glycoproteins I and E of varicella-zoster virus (VZV) using deletional mutations of VZV cosmids. Mallory S, Sommer M, Arvin AM. J Infect Dis. 1998: 178 Suppl 1 S22-6
• Isolation and utilization of human dendritic cells from peripheral blood to assay an in vitro primary immune response to varicella-zoster virus peptides. Jenkins DE, Yasukawa LL, Benike CJ, Engleman EG, Arvin AM. J Infect Dis. 1998: 178 Suppl 1 S39-42
• Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity. Sadzot-Delvaux C, Arvin AM, Rentier B. J Infect Dis. 1998: 178 Suppl 1 S43-7
• Herpes simplex virus type 2--a persistent problem. Arvin AM, Prober CG. N Engl J Med. 1997; 337 (16): 1158-9
• Reliability of a history of previous varicella infection in adults. Wallace MR, Chamberlin CJ, Zerboni L, Sawyer MH, Oldfield EC, Olson PE, Arvin AM. JAMA. 1997; 278 (18): 1520-2
• The varicella vaccine. Arvin AM, Curr Clin Top Infect Dis. 1997: 17 110-46
• The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (IE62) expressed in recombinant herpes simplex virus-1. Lowry PW, Koropchak CM, Choi CY, Mocarski ES, Kern ER, Kinchington PR, Arvin AM. Antiviral Res. 1997; 33 (3): 187-200
• Live attenuated varicella vaccine. Arvin AM, Pediatr Ann. 1997; 26 (6): 384-8
• Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, Arvin AM. J Infect Dis. 1997; 176 (3): 578-85
• Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes. Sadzot-Delvaux C, Kinchington PR, Debrus S, Rentier B, Arvin AM. J Immunol. 1997; 159 (6): 2802-6
• Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking. Mallory S, Sommer M, Arvin AM. J Virol. 1997; 71 (11): 8279-88
• T cell recognition and cytokine production elicited by common and type-specific glycoproteins of herpes simplex virus type 1 and type 2. Carmack MA, Yasukawa LL, Chang SY, Tran C, Saldana F, Arvin AM, Prober CG. J Infect Dis. 1996; 174 (5): 899-906
• Immune responses to varicella-zoster virus. Arvin AM, Infect Dis Clin North Am. 1996; 10 (3): 529-70
• Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA, Burchett SK, Jacobs RF, Starr SE, Whitley RJ. J Infect Dis. 1996; 174 (6): 1162-7
• Varicella vaccine in pregnancy. Seidman DS, Stevenson DK, Arvin AM. BMJ. 1996; 313 (7059): 701-2
• Treatment of adult varicella with sorivudine: a randomized, placebo-controlled trial. Wallace MR, Chamberlin CJ, Sawyer MH, Arvin AM, Harkins J, LaRocco A, Colopy MW, Bowler WA, Oldfield EC. J Infect Dis. 1996; 174 (2): 249-55
• Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Arvin AM, Moffat JF, Redman R. Adv Virus Res. 1996: 46 263-309
• Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Kimberlin D, Powell D, Gruber W, Diaz P, Arvin A, Kumar M, Jacobs R, Van Dyke R, Burchett S, Soong SJ, Lakeman A, Whitley R. Pediatr Infect Dis J. 1996; 15 (3): 247-54
• Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Ngai AL, Staehle BO, Kuter BJ, Cyanovich NM, Cho I, Matthews H, Keller P, Arvin AM, Watson B, White CJ. Pediatr Infect Dis J. 1996; 15 (1): 49-54
• Varicella-zoster virus: overview and clinical manifestations. Arvin AM, Semin Dermatol. 1996; 15 (2 Suppl 1): 4-7
• Varicella-zoster virus. Arvin AM, Clin Microbiol Rev. 1996; 9 (3): 361-81
• Live attenuated varicella vaccine. Arvin AM, Gershon AA. Annu Rev Microbiol. 1996: 50 59-100
• Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. Nader S, Bergen R, Sharp M, Arvin AM. J Infect Dis. 1995; 171 (1): 13-7
• Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. Moffat JF, Stein MD, Kaneshima H, Arvin AM. J Virol. 1995; 69 (9): 5236-42
• Aspects of the host response to varicella-zoster virus: a review of recent observations. Arvin AM, Neurology. 1995; 45 (12 Suppl 8): S36-7
• Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. Watson B, Rothstein E, Bernstein H, Arbeter A, Arvin A, Chartrand S, Clements D, Kumar ML, Reisinger K, Blatter M. J Infect Dis. 1995; 172 (1): 217-9
• New technology in the clinical microbiology laboratory: what you always wanted to know but were afraid to ask. Tompkins LS, Tenover F, Arvin A. J Infect Dis. 1994; 170 (5): 1068-74
• Tumor necrosis factor, interleukin-2, and interferon-gamma in adult varicella. Wallace MR, Woelfl I, Bowler WA, Olson PE, Murray NB, Brodine SK, Oldfield EC, Arvin AM. J Med Virol. 1994; 43 (1): 69-71
• Analysis of the epidemiology and pathogenesis of herpes simplex virus (HSV) infections in pregnant women and infants using the HSV-2 glycoprotein G antibody assay. Arvin AM, Prober CG. Infect Agents Dis. 1993; 2 (6): 375-82
• Immunization with the immediate-early tegument protein (open reading frame 62) of varicella-zoster virus protects guinea pigs against virus challenge. Sabella C, Lowry PW, Abbruzzi GM, Koropchak CM, Kinchington PR, Sadegh-Zadeh M, Hay J, Ruyechan WT, Arvin AM. J Virol. 1993; 67 (12): 7673-6
• Detection of antibodies to herpes simplex virus type 2 with a mammalian cell line expressing glycoprotein gG-2. Boucher FD, Yasukawa LL, Kerns K, Kastelein M, Arvin AM, Prober CG. Clin Diagn Virol. 1993; 1 (1): 29-38
• Investigation of the pathogenesis of varicella-zoster virus infection in guinea pigs by using polymerase chain reaction. Lowry PW, Sabella C, Koropchak CM, Watson BN, Thackray HM, Abbruzzi GM, Arvin AM. J Infect Dis. 1993; 167 (1): 78-83
• Multifocal leukoencephalitis caused by varicella-zoster virus in a child with leukemia: successful treatment with acyclovir. Carmack MA, Twiss J, Enzmann DR, Amylon MD, Arvin AM. Pediatr Infect Dis J. 1993; 12 (5): 402-6
• Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. J Infect Dis. 1992; 165 (1): 119-26
• Comparison of the Western immunoblot assay and a glycoprotein G enzyme immunoassay for detection of serum antibodies to herpes simplex virus type 2 in patients with AIDS. Safrin S, Arvin A, Mills J, Ashley R. J Clin Microbiol. 1992; 30 (5): 1312-4
• Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. Koropchak CM, Graham G, Palmer J, Winsberg M, Ting SF, Wallace M, Prober CG, Arvin AM. J Infect Dis. 1992; 165 (1): 188
• The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. Kinchington PR, Hougland JK, Arvin AM, Ruyechan WT, Hay J. J Virol. 1992; 66 (1): 359-66
• The management of pregnancies complicated by genital infections with herpes simplex virus. Prober CG, Corey L, Brown ZA, Hensleigh PA, Frenkel LM, Bryson YJ, Whitley RJ, Arvin AM. Clin Infect Dis. 1992; 15 (6): 1031-8
• Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Naumovski L, Quinn JP, Miyashiro D, Patel M, Bush K, Singer SB, Graves D, Palzkill T, Arvin AM. Antimicrob Agents Chemother. 1992; 36 (9): 1991-6
• Cell-mediated immunity to varicella-zoster virus. Arvin AM, J Infect Dis. 1992: 166 Suppl 1 S35-41
• Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. Sharp M, Terada K, Wilson A, Nader S, Kinchington PE, Ruyechan WT, Hay J, Arvin AM. J Infect Dis. 1992; 165 (5): 852-8
• Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. Kulhanjian JA, Soroush V, Au DS, Bronzan RN, Yasukawa LL, Weylman LE, Arvin AM, Prober CG. N Engl J Med. 1992; 326 (14): 916-20
• Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62. Lowry PW, Solem S, Watson BN, Koropchak CM, Thackray HM, Kinchington PR, Ruyechan WT, Ling P, Hay J, Arvin AM. J Gen Virol. 1992: 73 ( Pt 4) 811-9
• Herpes simplex virus infections: the genital tract and the newborn. Arvin AM, Prober CG. Pediatr Rev. 1992; 13 (3): 107-12
• Relationships between maternal immunity to herpes simplex virus and the risk of neonatal herpesvirus infection. Arvin AM, Rev Infect Dis. 1991 Nov-Dec: 13 Suppl 11 S953-6
• Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S, Arvin AM. Pediatrics. 1991; 87 (2): 166-70
• Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Frenkel LM, Brown ZA, Bryson YJ, Corey L, Unadkat JD, Hensleigh PA, Arvin AM, Prober CG, Connor JD. Am J Obstet Gynecol. 1991; 164 (2): 569-76
• A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J. N Engl J Med. 1991; 324 (7): 444-9
• Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S, Starr S, Jacobs R, Powell D, Nahmias A. N Engl J Med. 1991; 324 (7): 450-4
• Major histocompatibility complex restriction of T-cell responses to varicella-zoster virus in guinea pigs. Hayward AR, Burger R, Scheper R, Arvin AM. J Virol. 1991; 65 (3): 1491-5
• A controlled trial of acyclovir for chickenpox in normal children. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM, Feldman S, Gershon AA, Levy ML, Hayden GF, McGuirt PV. N Engl J Med. 1991; 325 (22): 1539-44
• Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus. Bergen RE, Sharp M, Sanchez A, Judd AK, Arvin AM. Viral Immunol. 1991; 4 (3): 151-66
• Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. Arvin AM, Sharp M, Smith S, Koropchak CM, Diaz PS, Kinchington P, Ruyechan W, Hay J. J Immunol. 1991; 146 (1): 257-64
• Herpes simplex virus infections. Arvin AM, Prober CG. Pediatr Infect Dis J. 1990; 9 (10): 765-7
• Use of polymerase chain reaction for successful identification of asymptomatic genital infection with herpes simplex virus in pregnant women at delivery. Hardy DA, Arvin AM, Yasukawa LL, Bronzan RN, Lewinsohn DM, Hensleigh PA, Prober CG. J Infect Dis. 1990; 162 (5): 1031-5
• The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. Bergen RE, Diaz PS, Arvin AM. J Infect Dis. 1990; 162 (5): 1049-54
• The T-lymphocyte response to varicella-zoster viral proteins. Arvin AM, Koropchak CM, Sharp M, Bergen R, Diaz PS. Adv Exp Med Biol. 1990: 278 71-81
• A prospective evaluation of primary genital herpes simplex virus type 2 infections acquired during pregnancy. Boucher FD, Yasukawa LL, Bronzan RN, Hensleigh PA, Arvin AM, Prober CG. Pediatr Infect Dis J. 1990; 9 (7): 499-504
• Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children. Englund JA, Arvin AM, Balfour HH. J Clin Microbiol. 1990; 28 (10): 2327-30
• Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. Kohl S, West MS, Prober CG, Sullender WM, Loo LS, Arvin AM. J Infect Dis. 1989; 160 (5): 770-6
• Serologic misdiagnosis of congenital infections. Arvin AM, Pediatr Infect Dis J. 1989; 8 (8): 542
• Antiviral susceptibilities of herpes simplex virus isolates from infants with recurrent mucocutaneous lesions after neonatal infection. Rabalais GP, Nusinoff-Lehrman S, Arvin AM, Levin MJ. Pediatr Infect Dis J. 1989; 8 (4): 221-3
• Genital herpes and the pregnant woman. Prober CG, Arvin AM. Curr Clin Top Infect Dis. 1989: 10 1-26
• Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. Koropchak CM, Solem SM, Diaz PS, Arvin AM. J Virol. 1989; 63 (5): 2392-5
• A concurrent epidemic of respiratory syncytial virus and echovirus 7 infections in an intensive care nursery. Wilson CW, Stevenson DK, Arvin AM. Pediatr Infect Dis J. 1989; 8 (1): 24-9
• T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. Diaz PS, Smith S, Hunter E, Arvin AM. J Immunol. 1989; 142 (2): 636-41
• Antiviral treatment of herpes simplex infection in neonates and pregnant women. Arvin AM, J Am Acad Dermatol. 1988; 18 (1 Pt 2): 200-3
• Immunity to whole varicella-zoster virus antigen and glycoproteins I and p170: relation to the immunizing regimen of live attenuated varicella vaccine. Diaz PS, Smith S, Hunter E, Arvin AM. J Infect Dis. 1988; 158 (6): 1245-52
• Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. Prober CG, Hensleigh PA, Boucher FD, Yasukawa LL, Au DS, Arvin AM. N Engl J Med. 1988; 318 (14): 887-91
• Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and infants with neonatal herpes. Sullender WM, Yasukawa LL, Schwartz M, Pereira L, Hensleigh PA, Prober CG, Arvin AM. J Infect Dis. 1988; 157 (1): 164-71
• Changing presentation of herpes simplex virus infection in neonates. Whitley RJ, Corey L, Arvin A, Lakeman FD, Sumaya CV, Wright PF, Dunkle LM, Steele RW, Soong SJ, Nahmias AJ. J Infect Dis. 1988; 158 (1): 109-16
• Humoral and cellular immunity to varicella-zoster virus glycoprotein gpI and to a non-glycosylated protein, p170, in the strain 2 guinea-pig. Arvin AM, Solem SM, Koropchak CM, Kinney-Thomas E, Paryani SG. J Gen Virol. 1987: 68 ( Pt 9) 2449-54
• Pharmacokinetics of acyclovir suspension in infants and children. Sullender WM, Arvin AM, Diaz PS, Connor JD, Straube R, Dankner W, Levin MJ, Weller S, Blum MR, Chapman S. Antimicrob Agents Chemother. 1987; 31 (11): 1722-6